World's Best Scientists 2026 revealed!
Massimo Aglietta

Massimo Aglietta

D-Index & Metrics

Medicine

D-Index
81
Citations
28230
World Ranking
16498
National Ranking
654

Massimo Aglietta publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Massimo Aglietta sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 721 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Massimo Aglietta D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Massimo Aglietta sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Massimo Aglietta is affiliated with the University of Turin in Italy and has contributed extensively to the field of medicine, particularly in oncology. Their research spans multiple subfields, including oncology, pulmonary and respiratory medicine, immunology, surgery, and cancer research, reflecting a broad engagement with both clinical and experimental aspects of cancer treatment and diagnostics.

The scientist's recent publications cover a range of topics relevant to cancer therapy and immunology. Notable papers include:

  • "Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study", 2023, The Lancet Oncology
  • "Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy", 2021, European Journal of Cancer
  • "Evolution of the Experimental Models of Cholangiocarcinoma", 2020, Cancers
  • "Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?", 2021, PharmacoEconomics - Open
  • "Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study", 2020, The Lancet Haematology

Their frequent co-authors include:

  • Dario Sangiolo
  • Sara Lonardi
  • Valeria Leuci
  • Giovanni Grignani
  • Marco Basiricò

Massimo Aglietta has published repeatedly in several leading scientific journals, with the highest number of publications appearing in:

  • Journal of Clinical Oncology
  • Cancers
  • Annals of Oncology
  • Clinical Cancer Research
  • Frontiers in Oncology

The main topics covered in their research include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Colorectal Cancer Treatments and Studies
  • Immune Cell Function and Interaction
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer

The scope of research performed by Massimo Aglietta reflects a comprehensive focus on innovative cancer treatments, with an emphasis on immunotherapy and the molecular characterization of cancer. Their work further includes the evaluation of experimental models and the economic aspects of genomic testing in clinical practice. The collaboration with multiple frequent co-authors and publication across several high-impact oncology journals indicates active engagement with the broader cancer research community.

Best Publications

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer

    Michael J. Overman;Sara Lonardi;Ka Yeung Mark Wong;Heinz Josef Lenz

  • Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate.

    Federico Bussolino;Ji Ming Wang;Paola Defilippi;F. Turrini

  • Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

    Giorgio Valabrega;F Montemurro;Massimo Aglietta

  • A comparison of allografting with autografting for newly diagnosed myeloma.

    Benedetto Bruno;Marcello Rotta;Francesca Patriarca;Nicola Mordini

  • Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood

    Wanda Piacibello;Fiorella Sanavio;Lucia Garetto;Antonella Severino

  • The release of platelet-activating factor from human endothelial cells in culture.

    G Camussi;M Aglietta;F Malavasi;C Tetta

  • Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood.

    Katia Mareschi;Eleonora Biasin;Wanda Piacibello;Massimo Aglietta

  • Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells.

    Wanda Piacibello;Fiorella Sanavio;Antonella Severino;Alessandra Danè

  • Expansion of Mesenchymal Stem Cells Isolated From Pediatric and Adult Donor Bone Marrow

    Katia Mareschi;Ivana Ferrero;Deborah Rustichelli;Simona Aschero

  • A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

    G Grignani;Emanuela Palmerini;P. Dileo;S. D. Asaftei

  • Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

    Giovanni Grignani;Emanuela Palmerini;Virginia Ferraresi;Lorenzo D'Ambrosio

  • Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells.

    F Bussolino;F Breviario;C Tetta;M Aglietta

  • Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.

    Laura Martincich;Filippo Montemurro;Giovanni De Rosa;Vincenzo Marra

  • Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils.

    G Camussi;M Aglietta;R Coda;F Bussolino

  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

    Chiara Cremolini;Carlotta Antoniotti;Daniele Rossini;Sara Lonardi

  • First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

    Heinz-Josef Lenz;Eric Van Cutsem;Maria Luisa Limon;Ka Yeung Mark Wong

  • Correlations between diffusion-weighted imaging and breast cancer biomarkers

    Laura Martincich;Veronica Deantoni;Ilaria Bertotto;Stefania Redana

  • Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures.

    F Bussolino;G Camussi;M Aglietta;P Braquet

  • Transmission of hepatitis C via blood splash into conjunctiva.

    M. Sartori;G. La Terra;M. Aglietta;A. Manzin

Frequent Co-Authors

Franca Fagioli
Franca Fagioli University of Turin
Federico Bussolino
Federico Bussolino University of Turin
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Anna Sapino
Anna Sapino University of Turin
Stefania Bruno
Stefania Bruno University of Turin
Mario Boccadoro
Mario Boccadoro University of Turin
Antonio Palumbo
Antonio Palumbo University of Turin
Vittorina Zagonel
Vittorina Zagonel Mario Negri Institute for Pharmacological Research
Paolo G. Casali
Paolo G. Casali University of Milan
Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers doesn't always mean committing to traditional, lengthy pathways. Many students begin with nursing, and one popular stepping stone is the average cost of rn to bsn programs. These programs provide an affordable route for registered nurses to obtain a Bachelor of Science in Nursing, boosting career options and salaries.

For those without a nursing background, direct entry msn programs offer a fast-track to a master’s degree in nursing. These online tracks are especially suitable for career changers eager to enter advanced nursing roles more rapidly.

Applicants concerned about competitive admissions can find guidance through lists of the easiest nursing schools to get into. These institutions can provide students with a valuable starting point—even for those with non-traditional academic backgrounds.

Alternatively, medical billing and coding is a growing healthcare field requiring less clinical training. Many accredited schools offer flexible online programs, and prospective students can explore financial aid for medical billing and coding online classes to make this pathway more affordable.

Best Scientists Citing Massimo Aglietta

Trending Scientists

Recently Published Articles